Luminex Plc · CSELK:LUMX.N0000
Luminex — 36th Annual J.P. Morgan Healthcare Conference (January 2018)
22 slides from Luminex's conference presentation, Jan 8, 2018
Slide 1: Investor Presentation – 36th Annual J.P. Morgan Healthcare Conference
Investor Presentation Nachum “Homi” Shamir President and Chief Executive Officer January 11, 2018 36th Annual J.P. Morgan Healthcare Conference
Slide 2: Safe Harbor Statement
© Copyright 2017 Luminex Corporation 2 Safe Harbor Statement Certain statements made during the course of this presentation may not be purely historical and consequently may be forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not li
Slide 3: Company at a Glance
© Copyright 2017 Luminex Corporation 3 Company at a Glance Empowering labs to obtain reliable, timely, and actionable answers; ultimately advancing health
Slide 4: Company at a Glance
© Copyright 2017 Luminex Corporation 4 Company at a Glance Razor / Razorblade; Expanding Footprint: Approaching 15,000 systems sold to date Expanding MDx portfolio and 100+ sales and support personnel Serve multi-billion dollar markets in life science research and clinical diagnostics 70+ partners i
Slide 5: Finished 2017 with Momentum in Molecular Testing
© Copyright 2017 Luminex Corporation 5 $238 $271 $306 2015 2016 2017 Finished 2017 with Momentum in Molecular Testing Sample to Answer Revenue ($M) Continues Strong Growth Trajectory* NOTE: Pro-forma 85 ARIES® and VERIGENE® Contracted Systems in 4Q17; Up from 60+ Contracted Systems in 3Q17 $21 $32 $
Slide 6: Luminex Corporation: A Diversified Business
© Copyright 2017 Luminex Corporation 6 Luminex Corporation: A Diversified Business LICENSED TECHNOLOGIES GROUP (LTG) Strong Profitability & Cash Flow MOLECULAR DIAGNOSTICS GROUP (MDx) Sample to Answer to Drive Growth Acceleration 2017 LTG - Related Revenue $142M High Margin Revenue accounts for $91M
Slide 7: Licensed Technologies Group
Licensed Technologies Group
Slide 8: Licensed Technologies Group: Overview
© Copyright 2017 Luminex Corporation 8 Licensed Technologies Group: Overview Royalty System Consumable LTG-Related Revenue, by Product: Other 13% % of Total LTG-Related Revenue, by Market: LTG: ~45% of total revenue ~40% ~40% ~20% Transplant Diagnostics Immuno-dx Protein Research …Luminex bead-based
Slide 9: Licensed Technologies Group: High Margin Revenue Trends
© Copyright 2017 Luminex Corporation 9 End-User Sales (Partner Reported)* $0 $50 $100 $150 $200 $250 $300 '02/'03 '04/'05 '06/'07 '08/'09 '10/'11 '12/'13 '14/'15 '16/'17 LMNX LTG Revenue: Total* $0 $200 $400 $600 $800 $1,000 $1,200 '02/'03 '04/'05 '06/'07 '08/'09 '10/'11 '12/'13 '14/'15 '16/'17 $0 $
Slide 10: Licensed Technologies Group: Key Takeaways
© Copyright 2017 Luminex Corporation 10 Licensed Technologies Group: Key Takeaways • 70+ partners investing in our technology; addressing large markets • Long-term contractual partnerships • Stable growth; highly profitable • Large and growing system base • New prototype in early stages
Slide 11: Molecular Diagnostics
Molecular Diagnostics: Sample to Answer
Slide 12: Entire VERIGENE and ARIES Infectious Disease test menu driving growth
© Copyright 2017 Luminex Corporation 12 Entire VERIGENE® and ARIES® Infectious Disease test menu driving growth $7M $10M $13M $18M 4Q15 4Q16 4Q17 4Q18E Quarterly Sample to Answer MDx Revenue* 40% 220+ VERIGENE® and ARIES® Systems placed under contract in 2017 NOTE: Approximate dollar amounts On Trac
Slide 13: Overview of Sample-to-Answer Active Customers
© Copyright 2017 Luminex Corporation 13 Large Hospital (BF) BC,EP,RP $1M Large Hospital (BF) EP $500K IDN Hospital Grp (BF) BC, EP $500K Large Hospital (Cult.) BC, EP RP $400K Overview of S2A Active Customers VERIGENE® platform continues strong traction. Blood Culture panels outpace market growth. E
Slide 14: The Right Solution for Customers Needs
© Copyright 2017 Luminex Corporation 14 The Right Solution for Customers Needs SYSTEM THROUGHPUT M U L T IP L E X IN G C A P A B IL IT IE S MAGPIX® Launched 2010 Luminex® 200™ Launched 2005 ARIES® Launched 2015 VERIGENE® Acquired 2016 Sample to Answer Non-Automated VERIGENE® II Target Launch: Early
Slide 15: Targeted & Syndromic Testing Solutions
© Copyright 2017 Luminex Corporation 15 Targeted & Syndromic Testing Solutions HSV 1&2 Flu/RSV GBS C. Difficile Norovirus GAS Bordetella Respiratory Panel GI Panel BCID Panel Targeted Syndromic Luminex is the only manufacturer providing Targeted & Syndromic solutions Clinical Studies in 2018: 7 (4 A
Slide 16: How We Win – Total Portfolio Selling
© Copyright 2017 Luminex Corporation 16 How We Win – Total Portfolio Selling Breadth of Solutions Superior Economic Value The Result • Platform Ease of Use; Throughput Options • Breadth of Menu: Targeted and Syndromic Tests • Lab Developed Test Optionality • LMNX Well Positioned for Potential Shifti
Slide 17: Financial Overview and Summary
Financial Overview and Summary
Slide 18: Ending 2017 With Strong Momentum; Well Positioned for 2018
© Copyright 2017 Luminex Corporation 18 Ending 2017 With Strong Momentum; Well Positioned for 2018 $265M Historical Annual Revenue ($M) $290M - $295M Luminex continues to generate significant cash flow during 2017 $124M 2017 Cash and Investments $31M 2017 Free Cash Flow Sample to Answer MDx revenue
Slide 19: Financial Overview: Transformation of Our Business
© Copyright 2017 Luminex Corporation 19 Financial Overview: Transformation of Our Business $175 - $200M $250 - $300M 60 - 65% NOTE: Slide does not include “other” revenue; 2017 margins are approximate figures based on preliminary estimates subject to adjustment during the closing process ; 5-year ta
Slide 20: Luminex Corporation: Investment Case Summary
© Copyright 2017 Luminex Corporation 20 Luminex Corporation: Investment Case Summary Licensed Technologies Group (LTG) Molecular Diagnostics Group (MDx) Financial Strength • Large and Growing System Base • 70+ Partners Investing in Our Technology; Long-term Contractual Partnerships; Addressing Large
Slide 21: Next Investor Event
© Copyright 2017 Luminex Corporation 21 Next Investor Event Fourth Quarter and Full Year 2017 Financial Results to be Released on February 12 after market close
Slide 22: Thank You
~ Thank You * e@ @ e Luminex. Ss complexity simplified.
Luminex — 36th Annual J.P. Morgan Healthcare Conference (January 2018) on 6ix